Actively Recruiting

Phase 2
Age: 1Year - 17Years
All Genders
NCT05753930

Imlifidase Prior to Kidney Transplant in Highly Sensitised Children

Led by Hansa Biopharma AB · Updated on 2026-04-24

10

Participants Needed

5

Research Sites

430 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn about the efficacy and safety of imlifidase in highly sensitized paediatric patients, 1-17 years old, with end stage renal disease (ESRD). The main questions it aims to answer are: * Does imlifidase treatment result in crossmatch conversion that enables transplantation? * How is the function of the transplanted kidney? The participants will be hospitalised in accordance with the normal routines for transplanted patients. The patients will receive medication to prevent rejection of the donor kidney, and because such treatment make the body more vulnerable medications to prevent infections.

CONDITIONS

Official Title

Imlifidase Prior to Kidney Transplant in Highly Sensitised Children

Who Can Participate

Age: 1Year - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent obtained from patient/parent/legal guardian/independent witness before any trial procedures
  • Highly sensitised patient with panel reactive antibodies (PRA) 80% or higher
  • Male or female patient between 1 to 17 years old at screening
  • Patient with end-stage renal disease waiting for kidney transplant from living or deceased donor
  • Patient must be transplantable (including size match) at consent
  • Previous unsuccessful desensitisation with plasmapheresis/IVIg/anti-CD20 or difficult anti-HLA antibody status
  • Positive crossmatch test against donor by flow cytometry or complement-dependent cytotoxicity, or virtual crossmatch for deceased donors
  • Willingness and ability to comply with the protocol as judged by investigator
Not Eligible

You will not qualify if you...

  • Previous treatment with imlifidase
  • Received IVIg treatment within 28 days before imlifidase
  • Desensitisation treatments within 1 month prior to transplantation
  • Hypersensitivity to imlifidase or related immunosuppressive drugs
  • Ongoing serious infections
  • Present or history of thrombotic thrombocytopenic purpura or family history
  • Severe conditions at transplantation like advanced heart failure, unstable coronary disease, active peripheral vascular disease, hypercoagulable conditions, or oxygen-dependent respiratory disease
  • Malignancy within 3 years before transplantation
  • ABO incompatible transplantations (except specific A2/A2B kidneys for B recipients)
  • Any other investigator-judged reason precluding transplantation
  • Breastfeeding or pregnancy
  • Fertile women sexually active without adequate contraception during trial
  • Suspected or confirmed COVID-19 infection
  • Positive HIV serology
  • Clinical signs of HBV, HCV, CMV, or EBV infections
  • Donor positive for HIV, HBV, HCV, CMV, or EBV when patient is negative
  • Active infections judged relevant by investigator
  • Tuberculosis or history of tuberculosis
  • Use of other investigational agents recently
  • Participation in medical device studies
  • Mental incapacity or language barriers affecting consent and trial understanding
  • Investigator judgment deeming participation impossible for other reasons

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

HUS, Helsinki University Hospital

Helsinki, Finland, 00290

Withdrawn

2

Robert Debre University Hospital

Paris, France, 75019

Actively Recruiting

3

Hospital Unviersitari Vall d'Hebron, Nefrología Pediátrica

Barcelona, Spain, 08035

Actively Recruiting

4

Karolinska University Hospital

Huddinge, Stockholm County, Sweden, SE-141 86

Actively Recruiting

5

Great Ormond Street Hospital for Children NHS Foundation Trust

London, United Kingdom, WC1N 3JH

Actively Recruiting

Loading map...

Research Team

C

Central Contact

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here